
NF1 & Koselugo (Selumetinib): Market Access Signals, Competitive Intelligence, and HCP Insight Design
Rare NF1 tumour burden, MEK inhibitor Koselugo (selumetinib)—FDA approvals for paediatrics (Apr 2020; expanded ≥1 y Sept 2025) and adults (Nov 2025)—EU adult expansion Autumn 2025. Commercial research design for specialists, carers, tenders, analogue analogies.
